Fortress Biotech(FBIO) - 2024 Q4 - Annual Results

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Exhibit 99.1 Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Recent Corporate Highlights1: Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carc ...